Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: No Mortality Gains From Remdesivir In WHO Trial, Gilead Questions Results

Trial Involved 11,000 Patients

Executive Summary

Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.

You may also be interested in...



Coronavirus Notebook: Adapted Comirnaty Vaccine Under EU Review, Sanofi & GSK Laud Next-Gen Booster

Valneva expects its vaccine candidate to be approved this month. Meanwhile, the core functions of the UK’s Vaccine Taskforce are to be transferred to the UK Health Security Agency and the Office for Life Sciences.

COVID-19: EU Veklury Approval To Be Renewed Despite Opposition

A European Parliament committee has rejected an attempt to stop the European Commission from renewing the conditional approval for Gilead’s Veklury for treating COVID-19.

Pandemic Perspectives: Remdesivir, Favipiravir’s Eventful Journeys In India A Year On

COVID-19 doesn't seem to be going away any time soon and antivirals remdesivir and favipiravir remain part of the treatment armamentarium. “Safety inventories” are in place for remdesivir in India, while a key physician anticipates an uptick in the use of favipiravir amid a surge in cases in some parts of the country.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC143148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel